A perspective of 30 years’ research in Alzheimer’s drug discovery

A perspective of 30 years’ research in Alzheimer’s drug discovery

Therapeutic approaches to Alzheimer’s disease (AD) that were tested and failed 25-30 years ago have now been approved by the FDA or have re-entered clinical trials. In the case of amyloid-beta-targeted monoclonals, the same side effects are observed (ARIA)  and the same level of confidence of clinical efficacy persist. A personal perspective includes research including GABAa receptors, NO/cGMP, calpain, cathepsin B, gamma-secretase, NAD, and APOE, some of which led to clinical trials. It is possible that progress has been hampered by seeing neurons as central to disease pathogenesis and hence therapeutic intervention.

Zoom Link:
https://arizona.zoom.us/j/87621383635